DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) - DECIPHERA PHARMACEUTICALS IN ownership

DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 124 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 0.06 and the average weighting 0.1%.

Quarter-by-quarter ownership
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) ownership history of DECIPHERA PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$87,737,548
-7.1%
6,897,606
+2.8%
1.93%
-4.1%
Q2 2023$94,434,926
+17.1%
6,707,026
+28.5%
2.02%
+12.2%
Q1 2023$80,627,957
+109.4%
5,218,638
+122.1%
1.80%
+125.5%
Q4 2022$38,503,847
-16.5%
2,349,228
-5.7%
0.80%
-13.2%
Q3 2022$46,093,000
-43.9%
2,491,490
-60.1%
0.92%
-45.8%
Q2 2022$82,200,000
+58.9%
6,250,964
+12.0%
1.70%
+46.5%
Q1 2022$51,731,000
-5.1%
5,580,4560.0%1.16%
+1.1%
Q4 2021$54,521,000
+96.9%
5,580,456
+584.7%
1.14%
+111.9%
Q3 2021$27,694,000
-43.7%
815,000
-39.3%
0.54%
-38.2%
Q2 2021$49,188,000
+107.5%
1,343,560
+154.2%
0.87%
+75.5%
Q1 2021$23,702,000
-21.4%
528,5850.0%0.50%
-16.4%
Q4 2020$30,166,000
+11.2%
528,5850.0%0.60%
-9.7%
Q3 2020$27,116,000
+7.7%
528,585
+25.4%
0.66%
-10.0%
Q2 2020$25,183,000
+3.8%
421,679
-28.5%
0.73%
-4.8%
Q1 2020$24,269,000
+26.6%
589,485
+91.4%
0.77%
+25.8%
Q4 2019$19,170,000
-5.0%
308,000
-48.2%
0.61%
-25.6%
Q3 2019$20,185,000
+47.3%
594,725
-2.1%
0.82%
+67.3%
Q2 2019$13,702,000
-2.8%
607,6330.0%0.49%
-9.1%
Q1 2019$14,103,000
+10.6%
607,6330.0%0.54%
+5.9%
Q4 2018$12,754,000
+67.4%
607,633
+80.8%
0.51%
+70.3%
Q4 2017$7,617,000
+23.4%
336,009
+3.4%
0.30%
+7.9%
Q3 2017$6,172,000325,0000.28%
Other shareholders
DECIPHERA PHARMACEUTICALS IN shareholders Q1 2022
NameSharesValueWeighting ↓
New Leaf Venture Partners, L.L.C. 1,209,571$11,213,0005.53%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 5,580,456$51,731,0001.16%
ARMISTICE CAPITAL, LLC 5,836,000$54,100,0001.05%
Pinz Capital Management, LP 165,835$1,537,0000.96%
Sunesis Advisors, LLC 96,299$893,0000.52%
Redmile Group, LLC 664,817$6,163,0000.19%
PDT Partners, LLC 222,343$2,061,0000.18%
Bayesian Capital Management, LP 41,900$388,0000.06%
Laurion Capital Management LP 459,290$4,258,0000.05%
Hennion & Walsh Asset Management, Inc. 101,643$942,0000.05%
View complete list of DECIPHERA PHARMACEUTICALS IN shareholders